Vipin Chandra: L-Leucine in Controlled Ovarian Hyperstimulation
Vipin Chandra, Director of Matcare Maternity, shared a post on LinkedIn:
“L-Leucine in Controlled Ovarian Hyperstimulation (COH):
A Metabolic Adjuvant Worth Serious Clinical Attention
Poor ovarian response remains one of the most frustrating challenges in ART. Despite protocol refinement and gonadotropin escalation, outcomes often plateau—especially in women with diminished ovarian reserve (DOR) and hypo-responsive follicles.
Increasingly, attention is shifting upstream—from hormones alone to the intracellular metabolic pathways that govern follicular competence.
One nutrient drawing justified mechanistic interest is L-Leucine.
Why L-Leucine Matters Biologically
L-Leucine is a branched-chain amino acid and the most potent physiological activator of the mTOR pathway, a central regulator of:
- granulosa cell proliferation
- protein synthesis
- mitochondrial function
- steroidogenesis
- follicular growth and survival
mTOR signaling is now well established as essential for follicular activation and oocyte competence.
Adhikari et al., PNAS 2010
Mechanistic Advantage in Low-Reserve Ovaries
Unlike insulin-dependent activators, L-Leucine directly activates mTORC1 via Rag-GTPase signaling, supporting cellular metabolism even under stress conditions—precisely the environment seen in aging or hypo-responsive ovaries.
Wolfson et al., Science 2016
Granulosa cells are highly amino-acid sensitive, and preclinical work shows leucine improves:
- mitochondrial activity
- steroidogenic capacity
- granulosa cell survival
Zhang et al., Biology of Reproduction 2017
What Clinical Data Suggest So Far
While IVF-specific RCTs isolating L-Leucine are limited, human nutritional and metabolic studies consistently suggest that optimizing amino-acid–mTOR signaling improves ovarian responsiveness.
L-Leucine has also been studied as part of multi-nutrient metabolic strategies, commonly combined with:
- myo-inositol (FSH/insulin signaling, oxidative stress reduction)
- selenium (steroidogenesis, antioxidant support)
Genazzani et al., Gynecological Endocrinology 2018
Palomba et al., Human Reproduction Update 2021
Clinical Interpretation (Balanced, Not Hype)
At present, L-Leucine should be viewed as a metabolic adjuvant—not a standalone solution.
Its potential role appears strongest in:
- DOR / POSEIDON low-prognosis patients
- hypo-responsive granulosa cell environments
- aging ovaries with metabolic stress
When combined thoughtfully with agents like myo-inositol and selenium, L-Leucine may offer dual-pathway support:
mTOR activation + insulin/FSH signaling optimization
What is urgently needed:
- well-designed RCTs isolating L-Leucine
- follicular-fluid and granulosa-cell human studies
- POSEIDON-stratified outcome analysis.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jun 19, 2026, 15:54Horace Roman: Sciatic Nerve Endometriosis – Prevent Muscle Atrophy Caused by Progressive Denervation
-
Jun 19, 2026, 15:36Why Does the Clock Read Older? – Fertility Plus
-
Jun 19, 2026, 15:28Asma Khalil: Study Raises Questions About Workplace Activities and Early Pregnancy Outcomes
-
Jun 19, 2026, 15:21Spindle Dynamics and Chromosome Segregation In Human Preimplantation Embryos – Fertility and Sterility
-
Jun 19, 2026, 15:12Today is World Sickle Cell Day – Preeclampsia Foundation
-
Jun 19, 2026, 14:59Marco Zaccaria: ESGE Webinar to Spotlight Advances in the Surgical Management of Parametrial Endometriosis
-
Jun 19, 2026, 14:46PMOS Does Not Make Conception Impossible – PCOS Awareness Association
-
Jun 19, 2026, 14:40Diana Kayal: Successful Fertility Programs Aren’t Built On Clinical Expertise Alone
-
Jun 19, 2026, 14:29Devyanshi Dixit: Call for Abstracts at GFWH 2026